<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02056847</url>
  </required_header>
  <id_info>
    <org_study_id>JW-PTV-713</org_study_id>
    <nct_id>NCT02056847</nct_id>
  </id_info>
  <brief_title>to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia</brief_title>
  <acronym>SIPHON</acronym>
  <official_title>Randomized, Open-label, Multi-centered Study to Evaluate the Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia(Phase 4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yeungnam University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eulji University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective&#xD;
&#xD;
      : To evaluate that there is no different effect on HbA1c between routine lipid lowering&#xD;
      therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic&#xD;
      patients with impaired fasting glucose (IFG).&#xD;
&#xD;
      H0: µT-µC ≥ 0.4 vs H1: µT-µC &lt; 0.4&#xD;
&#xD;
      µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the&#xD;
      control drug (Pitavastatin 2 MG)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigational Product Test group: Pitavastatin calcium (LIVALO) 4mg tab Control group:&#xD;
      Pitavastatin calcium (LIVALO) 2mg tab&#xD;
&#xD;
      Study Site: Multi-centers in Korea&#xD;
&#xD;
      Period: For 24months after IRB approval at each site (Including 12months of subject&#xD;
      enrollment period)&#xD;
&#xD;
      Efficacy End points&#xD;
&#xD;
      A. Primary end point The change of HbA1c before and after taking LIVALO&#xD;
&#xD;
      B. Secondary end point&#xD;
&#xD;
        1. Incidence of diabetes within 1year after registration (based; FPG ≥126mg/dL or to need&#xD;
           taking diabetes medication)&#xD;
&#xD;
        2. Incidence of major cardiovascular (TLR-MACE) events within 1 year after registration&#xD;
&#xD;
        3. Incidence of total cardiovascular (TVR-MACE) events within 1 year after registration&#xD;
&#xD;
        4. The change of the lipid composition (T-chol, TG, LDL-C, HDL-C, ApoA1/ApoB)&#xD;
&#xD;
        5. The changes of hs-CRP&#xD;
&#xD;
        6. The changes of Adiponectin&#xD;
&#xD;
        7. The change of blood glucose and Insulin levels FPG(Fasting Plasma Glucose) Fasting Serum&#xD;
           Insulin HOMA IR [fasting insulin(µIU/mL) X fasting glucose(mg/dL)]/405 HOMA β [360 X&#xD;
           fasting insulin(µIU/mL)]/[fasting glucose(mg/dL)-63]&#xD;
&#xD;
      Statistical Methods&#xD;
&#xD;
        1. Efficacy A. Primary efficacy endpoint analysis Describe statistics of basic about the&#xD;
           HbA1c variation before and after taking LIVALO by groups. In order to verify&#xD;
           noninferiority of test drug, check that upper limit of confidence interval of the&#xD;
           one-sided 97.5% is less than 0.4% about difference of HbA1c variation between the&#xD;
           control group and the test group, before and after taking LIVALO.&#xD;
&#xD;
           B. Secondary efficacy endpoint analysis Continuous variables&#xD;
&#xD;
           :Present the mean, standard deviation, minimum, and maximum values for TC, TG, LDL-C,&#xD;
           HDL-C, Fasting serum insulin, Fasting plasma glucose and HOMA IR, HOMA β etc. by each&#xD;
           visit and in each group. In comparison with intergroup, using two-sample t-test for&#xD;
           normal distribution and using Wilcoxon rank sum test for non-normal distribution. Also&#xD;
           In comparison with the same group, using paired t-test for normal distribution and using&#xD;
           Wilcoxon signed rank test for non-normal distribution.&#xD;
&#xD;
           Discrete variables&#xD;
&#xD;
           : The number and percentage of the subjects for incidence of DM and cardiovascular event&#xD;
           are described of each group and the ratio of the intergroup comparison use χ2-test or&#xD;
           Fisher's exact test.&#xD;
&#xD;
        2. Safety All the AEs and the ADRs which manifested more than once are described by the&#xD;
           frequency and percentage of each group and use χ2-test or Fisher's exact test for&#xD;
           intergroup comparison about the rate of AEs and ADRs Laboratory tests and vital signs&#xD;
           are analyzed descriptive statistics quantity of each group, and in comparison with&#xD;
           intergroup, use two-sample t-test for normal distribution and use Wilcoxon rank sum test&#xD;
           for non-normal distribution. Also, In comparison with the same group, use paired t-test&#xD;
           for normal distribution and use Wilcoxon signed rank test for non-normal distribution.&#xD;
&#xD;
      Clinical laboratory test is analyzed the frequency and percentage of the outside normal range&#xD;
      of subjects, and using χ2-test or Fisher's exact test with intergroup.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of HbA1c before and after taking LIVALO®</measure>
    <time_frame>24 weeks after taking IP</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of diabetes</measure>
    <time_frame>within 1year after registration</time_frame>
    <description>based; FPG ≥126mg/dL or to need taking diabetes medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of total cardiovascular (TVR-MACE) events</measure>
    <time_frame>within 1 year after registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of the lipid composition (T-chol, TG, LDL-C, HDL-C, ApoA1/ApoB)</measure>
    <time_frame>24weeks and 1 year after registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of hs-CRP, Adiponectin, blood glucose and Insulin levels</measure>
    <time_frame>24weeks and 1 year after registration</time_frame>
    <description>The change of blood glucose and Insulin levels FPG(Fasting Plasma Glucose) Fasting Serum Insulin HOMA IR [fasting insulin(µIU/mL) X fasting glucose(mg/dL)]/405 HOMA β [360 X fasting insulin(µIU/mL)]/[fasting glucose(mg/dL)-63]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">313</enrollment>
  <condition>HbA1c Level Associated With Lipid Compositions</condition>
  <arm_group>
    <arm_group_label>Pitavastatin calcium 4mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pitavastatin calcium (LIVALO®) 4mg, once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pitavastatin calcium 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pitavastatin calcium (LIVALO®) 2mg, once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin calcium 4mg</intervention_name>
    <description>taking once a day</description>
    <arm_group_label>Pitavastatin calcium 4mg</arm_group_label>
    <other_name>Pitavastatin calcium(LIVALO) 4mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin calcium 2mg</intervention_name>
    <description>Taking once a day</description>
    <arm_group_label>Pitavastatin calcium 2mg</arm_group_label>
    <other_name>LIVALO 2mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and Female patients who are more than 20 years old or 70 years old or less.&#xD;
&#xD;
          2. Patient who voluntarily sign on written informed consent form&#xD;
&#xD;
          3. Patient who LDL-C ≥ 100mg/dl or was diagnosed with hyperlipidemia&#xD;
&#xD;
          4. Patient who was suspected with Imparied Fasting Glucose (IFG) and satisfy FPG level ≥&#xD;
             100mg/dL and &lt; 126mg/dL when FPG measured twice.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who has familial hypercholesterolemia&#xD;
&#xD;
          2. Patient who has been diagnosed with Type1, Type2 DM or secondary DM(diabetes mellitus)&#xD;
             at the screening visit (Diagnostic criteria of DM: HbA1c≥ 6.5%)&#xD;
&#xD;
          3. Patient who has received antidiabetic within 6weeks to the screening visit&#xD;
&#xD;
          4. Patient who has been taking insulin continuously or to be needed in the future&#xD;
&#xD;
          5. Patient who has a history of gastrectomy&#xD;
&#xD;
          6. Patient who is suspected or diagnosed with malignant tumor within last 10 years&#xD;
&#xD;
          7. Patient who has serious pancreatic disease or endocrine disorders&#xD;
&#xD;
          8. Patient who currently takes Cyclosporine&#xD;
&#xD;
          9. Patient who has a medical history of hypersensitivity to Pitavastatin calcium&#xD;
&#xD;
         10. Patient who has suspected renal failure (serum creatinine ≥2.0 mg/dL)&#xD;
&#xD;
         11. Patient who has suspected liver dysfunction (more than 2.5 times the upper limit of&#xD;
             normal AST or ALT)&#xD;
&#xD;
         12. Patient who has more than 3 times the upper limit of normal CPK&#xD;
&#xD;
         13. Patient who is breastfeeding, pregnant or planning pregnancy&#xD;
&#xD;
         14. Patient who deemed inappropriate as subject in the opinion of the Principal&#xD;
             Investigator or Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NamSik Chung, M.D., Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JW pharmaceutical</name>
      <address>
        <city>Seoul</city>
        <zip>137-864</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2014</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Livalo, pitavastatin, hyperlipidemia, IFG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

